In case you missed it, PwC Health Research Institute’s (HRI) Medical Cost Trend: Behind the Numbers 2017 report highlights medicine spending is “still a relatively small portion of overall health spending and, as such, concerns of ever-increasing cost growth from new cures may trigger false alarms.”
Topics: drug cost
Access to prescription medicines is critical to help patients manage their chronic conditions and maximize quality of life. Unfortunately, even with insurance coverage, many patients still struggle to get the medicines they need due to high out-of-pocket costs and other plan restrictions. We looked at the burden on patients with health insurance exchange coverage in 2014 and 2015. Now, we’re taking a look at 2016 coverage.
Topics: Access, Cystic Fibrosis, health insurance, HIV/AIDS, Burden on Patients, Multiple Sclerosis, exchanges, Mental Health, Oncology, Access Better Coverage, ABCs of Coverage, Policy Solutions, Empower Consumers
Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with Marisa Schauerhamer, a 2016 PhRMA Foundation Young Investigator Adherence grantee, about her research on how value-based insurance design affects medication adherence for patients with diabetes.
Back in April, we previewed MedPAC’s recommendations and expressed concern and opposition to the sweeping recommended changes to Part D that taken together could harm beneficiaries by eroding coverage and protections for many of the most vulnerable enrollees in the program.
America’s biopharmaceutical research companies are committed to developing new treatments and cures that improve health and save patient lives. Jen O’Neil, principal oncology scientist at Merck, recently shared her story about the importance of collaboration in the research and development process and how this environment inspires her despite the setbacks along the way.
The United States is not only falling behind other countries on many key science, technology, engineering and mathematics (STEM) indicators, but our public investment in STEM education has steadily declined at the same time that other countries—including our biggest global competitors—are making substantial investments. The choices we make now will impact America’s global competitiveness and economic growth for years to come.
A well-informed consumer is an engaged and empowered patient. One policy solution for delivering innovative treatments to patients is to engage and empower consumers by making more information about health care out-of-pocket costs available.
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.
We’re pleased to host a guest blog from Professor MP Pugatch, the IPKM Professor of Valorisation, Entrepreneurship and Management at the University of Maastricht and Managing Director of Pugatch Consilium, a boutique research consultancy.
Last week I had the pleasure of attending the 2016 BIO International Convention hosted in San Francisco, California. The biggest global event of its kind, this international convention brings together stakeholders from all across biotechnology, including from the biopharmaceutical sector. Going from panel to panel and meeting to meeting, I was struck by the number of times the topic of ‘localization’ came up.
Jen and Yingzi are in the problem-solving business.
Every day, they tackle one of the toughest health care problems: cancer. While many others like them across the biopharmaceutical industry work tirelessly in pursuit of new treatments and cures in other disease areas for America’s patients.
As we’ve learned in recent case studies, the specific course of treatment chosen for a patient managing a serious disease can have real implications for their quality of life. Patients and their physicians must weigh the pros and cons to determine the best treatment option to meet their individual needs.